siRNA Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 6.7 billion
Estimated Base Value
2035 Forecast
US$ 32.8 billion
Projected Market Value
CAGR 2026–2035
17.2%
Compound Annual Growth
Largest Segment
Chemically Modified siRNA
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Arrowhead Pharmaceuticals
Emerging Players
ADARx Pharmaceuticals, Aligos Therapeutics
siRNA Therapeutics Market Overview
The siRNA Therapeutics market involves the research, development, and commercialization of pharmaceutical products that use small interfering RNA (siRNA) technology. These therapeutics work by silencing specific disease-causing genes, inhibiting the production of detrimental proteins. This market primarily addresses the treatment of various conditions, including genetic disorders, oncology, infectious diseases, and neurological conditions. Buyers in this market include hospitals, specialty clinics, research and academic institutions, biopharmaceutical companies, contract research organizations, and diagnostic laboratories.
The siRNA Therapeutics market is estimated at $6.7 Bn in 2025 and is forecast to reach $32.8 Bn in 2035, growing at a CAGR of 17.2% from 2025 to 2035. This growth is driven by the rising prevalence of genetic and chronic diseases, coupled with advancements in RNA interference technology and delivery systems. Increased investment in the biotechnology sector also contributes to market expansion. However, challenges such as efficient and specific delivery of siRNA to target cells, high development and manufacturing costs, and potential off-target effects act as restraints.
The market is segmented by Type (Chemically Modified Sirna, Unmodified Sirna, Conjugated Sirna, Self-Delivering Sirna, Dicer Substrate Sirna), Application (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Ocular Diseases, Liver Diseases, Others), Technology (Lipid Nanoparticles, Galnac Conjugates, Polymer-Based Delivery Systems, Viral Vectors, Exosome-Based Delivery, Peptide Conjugates, Antibody Conjugates, Others), End-User (Hospitals, Specialty Clinics, Research & Academic Institutions, Biopharmaceutical Companies, Contract Research Organizations, Diagnostic Laboratories), Form (Injectable Formulations, Topical Formulations, Ocular Formulations, Pulmonary Formulations, Oral Formulations, Implantable Devices), and Stage (Discovery and Pre-Clinical Stage, Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, Commercialized Products). It is served across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Leading companies include Arrowhead Pharmaceuticals, Silence Therapeutics, Avidity Biosciences, OliX Pharmaceuticals, Sirnaomics, Arbutus Biopharma, ReCode Therapeutics, Quark Pharmaceuticals, Exicure, Ascletis Pharma, Suzhou Ribo Life Science, and Bio-Path Holdings. The full report covers global market analysis, segmentation by disease application, delivery technology, and end-user, along with comprehensive market sizing and forecasts.
Market Definition & Overview
The siRNA Therapeutics market encompasses the research, development, manufacturing, and commercialization of pharmaceutical products utilizing small interfering RNA (siRNA) technology. These therapeutics are designed to harness the natural RNA interference (RNAi) pathway to silence specific disease-causing genes at the post-transcriptional level, thereby inhibiting the production of detrimental proteins. This market primarily targets the treatment of various diseases including genetic disorders, oncology, infectious diseases, and neurological conditions, representing a significant advancement in precision medicine within the broader RNA therapeutics industry.
Scope
- Global market analysis across major regions and countries.
- Segmentation by disease application, delivery technology, and end-user.
- Comprehensive market sizing and forecast from 2025 to 2035.
Inclusions
- Approved small interfering RNA (siRNA) drugs for human therapeutic use.
- siRNA drug candidates in various stages of clinical development.
- Delivery technologies specifically developed for siRNA therapeutics.
- Manufacturing and supply chain activities for siRNA products.
- Revenue from sales of commercialized siRNA therapeutic agents.
- R&D expenditure focused on novel siRNA mechanisms and targets.
Exclusions
- Antisense oligonucleotide (ASO) therapies and mRNA vaccines.
- siRNA research reagents and diagnostic kits.
- CRISPR-Cas9 or other gene-editing technologies.
- Exosomes or viral vector-based gene therapies unrelated to siRNA.
- Traditional small molecule drugs or protein biologics.
- Non-therapeutic applications of RNA interference.
Market Size Forecast
Executive Summary
• The siRNA Therapeutics market is valued at $6.7 Bn in 2025 and is forecast to reach $32.8 Bn by 2035, reflecting a robust CAGR of 17.2% as demand accelerates across every major segment and region over the ten-year outlook.
• Chemically Modified siRNA leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying competition from emerging biotech and established pharmaceutical giants is driving strategic collaborations and targeted M&A, reshaping the siRNA landscape through advanced delivery system innovations and pipeline diversification across rare and chronic diseases.
• Expanded therapeutic applications beyond rare diseases, particularly into chronic conditions like cardiovascular and metabolic disorders, alongside advancing delivery technologies, will fuel sustained long-term market expansion and investment opportunities globally.
• Breakthroughs in extrahepatic delivery and gene editing integration are critical technological advancements, navigating evolving regulatory pathways that prioritize safety and efficacy while accelerating novel siRNA therapeutic approvals across key regions.
• The oncology and CNS segments represent significant untapped potential, demanding region-specific R&D investments and tailored market access strategies to overcome delivery challenges and address unmet medical needs effectively.
• Robust investment in specialized manufacturing capabilities and cold chain logistics is essential, ensuring scalable production and global distribution efficiency for novel siRNA therapies as pipeline assets approach commercialization.
• Successful market penetration hinges on demonstrating superior long-term efficacy and patient convenience, compelling innovators to differentiate through proprietary delivery platforms and strategic portfolio expansion in high-growth therapeutic areas.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The siRNA Therapeutics Market was valued at $6.7 billion in its base year, establishing a significant foundation for future expansion.
Future Market Scale
The market is projected to reach an impressive $32.8 billion by the forecast year, indicating substantial growth and increasing therapeutic adoption.
Exceptional Growth Rate
A robust Compound Annual Growth Rate (CAGR) of 17.2% highlights the rapid expansion and escalating demand for siRNA-based therapies.
Substantial Market Growth
Overall, the market is set for nearly a seven-fold expansion, growing from $6.7 billion to $32.8 billion, driven by scientific advancements.
Therapeutic Area Expansion
Expansion into novel therapeutic areas, particularly rare genetic disorders and chronic diseases, represents a leading segment driving market growth.
Delivery System Innovations
A notable trend fueling market development is continuous innovation in siRNA delivery systems, improving efficacy and patient accessibility.
Market Dynamics
Market Trends
- Increased R&D for novel siRNA delivery systems.
- Growing focus on extrahepatic targets beyond liver.
- Expansion into chronic diseases and rare genetic disorders.
- Strategic collaborations and partnerships are becoming common.
Growth Drivers
- Rising prevalence of genetic and chronic diseases.
- Advancements in RNA interference technology and delivery.
- Increased investment and funding in biotech sector.
- Favorable regulatory landscape supporting orphan drugs.
Restraints
- Efficient and specific delivery of siRNA to target cells remains a significant challenge.
- High development and manufacturing costs hinder broader market adoption.
- Potential for off-target effects and immunogenicity raises safety concerns.
- Complex regulatory pathways and stringent approval processes impede market entry.
Opportunities
- Developing siRNA therapies for previously untreatable conditions.
- Exploring combination therapies to enhance efficacy.
- Expanding applications into oncology, neurology, and infectious diseases.
- Leveraging AI/ML for drug discovery and target identification.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Chemically Modified SirnaUnmodified SirnaConjugated SirnaSelf-Delivering SirnaDicer Substrate Sirna |
| By Application | OncologyGenetic DisordersInfectious DiseasesCardiovascular DiseasesNeurological DisordersOcular DiseasesLiver DiseasesOthers |
| By Technology | Lipid NanoparticlesGalnac ConjugatesPolymer-Based Delivery SystemsViral VectorsExosome-Based DeliveryPeptide ConjugatesAntibody ConjugatesOthers |
| By End-User | HospitalsSpecialty ClinicsResearch & Academic InstitutionsBiopharmaceutical CompaniesContract Research OrganizationsDiagnostic Laboratories |
| By Form | Injectable FormulationsTopical FormulationsOcular FormulationsPulmonary FormulationsOral FormulationsImplantable Devices |
| By Stage | Discovery and Pre-Clinical StagePhase I Clinical TrialsPhase II Clinical TrialsPhase III Clinical TrialsCommercialized Products |
Regional Analysis
- North America leads the siRNA therapeutics market due to substantial R&D investments, a robust presence of major pharmaceutical companies, and a favorable regulatory environment. High healthcare expenditure and advanced infrastructure also significantly contribute to its dominance.
- Asia-Pacific is emerging as the fastest-growing region, driven by the escalating prevalence of chronic diseases and increasing healthcare expenditure. Expanding pharmaceutical R&D, rising patient awareness, and government initiatives supporting biotechnology advancements fuel this rapid market expansion.
- Europe demonstrates a noteworthy trend with an increasing focus on developing siRNA therapies for rare genetic diseases and personalized medicine approaches. Collaborative research initiatives between academic institutions and biotech firms, coupled with government funding, are driving innovation in this specialized segment.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- North America leads the siRNA therapeutics market due to significant R&D investments, a strong presence of key pharmaceutical and biotech companies, and advanced healthcare infrastructure.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Latin America demonstrates promising growth in siRNA therapeutics, attributed to improving healthcare access, increasing awareness of advanced treatments, and a growing patient pool in key markets such as Brazil and Mexico.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Europe holds a substantial share, driven by robust research funding, a well-established pharmaceutical industry, and increasing regulatory support for novel RNA-based therapies.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- The Asia Pacific region is rapidly expanding, fueled by rising healthcare expenditure, increasing incidence of chronic diseases, and growing R&D activities in countries like China, Japan, and India.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region exhibits high growth potential from a smaller base, driven by increasing government investments in healthcare infrastructure and a rising demand for advanced therapies for genetic and chronic diseases.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads the siRNA therapeutics market due to extensive R&D investments, a robust biotech ecosystem, and a concentration of major pharmaceutical companies driving innovation and commercialization. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As the largest economy in South America, Brazil presents a significant patient population and increasing investment in its healthcare sector, making it a growing market for advanced therapies. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany's robust pharmaceutical industry, advanced healthcare system, and strong research infrastructure position it as a key European market for siRNA therapeutics development and adoption. |
| 4 | China | US$ XX.X Mn | XX.X% | China is experiencing rapid growth in its biotech sector, fueled by massive patient populations, increasing R&D investment, and strong government support for innovative drug development, including siRNA. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is increasing its healthcare spending and actively developing its local pharmaceutical industry and research capabilities, driving demand for innovative treatments like siRNA. |
Countries Covered (28)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Netherlands, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Taiwan, Australia, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Arrowhead Pharmaceuticals | XX.X% | Utilizes its proprietary TRiM platform to deliver RNAi therapeutics to various cell types, primarily targeting liver and lung diseases. | — | — | ARO-APOC3ARO-ANG3ARO-C3+1 |
| 2 | Silence Therapeutics | XX.X% | Develops novel siRNA therapeutics using its proprietary mRNAi GOLD platform, focusing on hematological and cardiovascular diseases. | — | — | SLN360SLN124SLN501 |
| 3 | Avidity Biosciences | XX.X% | Pioneers the development of Antibody Oligonucleotide Conjugates (AOCs) to deliver RNA therapeutics to specific cell types and tissues beyond the liver. | — | — | AOC 1001AOC 1020AOC 1044 |
| 4 | OliX Pharmaceuticals | XX.X% | Focuses on developing therapeutic siRNAs using its proprietary 'cell-permeable self-delivering RNAi (cp-siRNA)' technology for various diseases, including dermatology, ophthalmology, and oncology. | — | — | OLX101OLX301AOLX702A |
| 5 | Sirnaomics | XX.X% | Develops RNAi therapeutics for a wide range of diseases, particularly oncology and fibrotic diseases, leveraging its proprietary pH-sensitive polymer nanoparticle (PNP) delivery system. | — | — | STP705STP707STP702 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (19)
Arrowhead Pharmaceuticals, Silence Therapeutics, Avidity Biosciences, OliX Pharmaceuticals, Sirnaomics, Arbutus Biopharma, ReCode Therapeutics, Quark Pharmaceuticals, Exicure, Ascletis Pharma, Suzhou Ribo Life Science, Bio-Path Holdings, TransCode Therapeutics, miCure Therapeutics, Veritas Therapeutic, Evrys Bio, AttoVax, Nurex Therapeutics, Genevant Sciences
The global siRNA Therapeutics market features a competitive landscape led by Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Avidity Biosciences, OliX Pharmaceuticals, and Sirnaomics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Arrowhead Pharmaceuticals
Silence Therapeutics
Avidity Biosciences
OliX Pharmaceuticals
Sirnaomics
Arbutus Biopharma
ReCode Therapeutics
Quark Pharmaceuticals
Exicure
Ascletis Pharma
Suzhou Ribo Life Science
Bio-Path Holdings
TransCode Therapeutics
miCure Therapeutics
Veritas Therapeutic
Evrys Bio
AttoVax
Nurex Therapeutics
Genevant Sciences
ADARx Pharmaceuticals
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Alnylam Reports Positive Phase 1 Data for Hypertension siRNA Therapeutic
Alnylam Pharmaceuticals announced promising Phase 1 results for ALN-K8, an investigational RNAi therapeutic targeting hypertension, demonstrating significant and sustained reductions in blood pressure and opening a potentially large new market.
Silence Therapeutics Enters Collaboration with Mallinckrodt for Rare Disease Program
Silence Therapeutics forged a strategic partnership and licensing agreement with Mallinckrodt for SLN501, an siRNA therapeutic targeting C3 for complement-mediated diseases, securing an upfront payment and potential milestone earnings.
Novartis Highlights Strong Global Uptake and Data for Leqvio (inclisiran)
Novartis, commercializing Alnylam's Leqvio (inclisiran), reported robust uptake and reiterated strong long-term efficacy and safety data from studies like ORION-8, solidifying the siRNA therapeutic's position in cardiovascular disease management.
Arrowhead and Takeda Advance Fazirsiran into Pivotal Phase 3 for AATD-LD
Arrowhead Pharmaceuticals, in collaboration with Takeda, provided updates on the continued advancement of their investigational siRNA therapeutic, fazirsiran, through pivotal Phase 3 trials for alpha-1 antitrypsin deficiency-associated liver disease, nearing potential market approval.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $6.7 Bn |
| Market Size (Forecast) | $32.8 Bn |
| CAGR | 17.2% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 28 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 31 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the siRNA Therapeutics Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The siRNA Therapeutics market is estimated at $6.7 Bn in 2025. It is forecast to reach $32.8 Bn in 2035, indicating substantial growth over the forecast period.
The siRNA Therapeutics market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 17.2% from 2025 to 2035. This growth is driven by advancements in technology and rising disease prevalence.
The main segments include Type, Application, Technology, End-User, Form, and Stage. Key applications are Oncology and Genetic Disorders, while technologies include Lipid Nanoparticles and Galnac Conjugates.
Leading companies include Arrowhead Pharmaceuticals, Silence Therapeutics, Avidity Biosciences, OliX Pharmaceuticals, Sirnaomics, Arbutus Biopharma, ReCode Therapeutics, Quark Pharmaceuticals, Exicure, Ascletis Pharma, Suzhou Ribo Life Science, and Bio-Path Holdings.
The report covers global market analysis, segmentation by disease application, delivery technology, and end-user. It also provides comprehensive market sizing and forecasts for the period from 2025 to 2035, offering insights into market dynamics.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Alzheimer's Disease Therapeutics Market
$8.6 Bn in 2025 · 11.9% CAGR
Atopic Dermatitis Therapeutics Market
$18.7 Bn in 2025 · 8.4% CAGR
Autoimmune Disease Therapeutics Market
$168.0 Bn in 2025 · 6.1% CAGR
Computational Therapeutics Market
$600.0 Mn in 2025 · 18.6% CAGR
Epilepsy Therapeutics Market
$5.8 Bn in 2025 · 7.7% CAGR
Exosome Therapeutics Market
$186.1 Mn in 2025 · 28.6% CAGR
Inflammatory Bowel Disease Therapeutics Market
$27.6 Bn in 2025 · 5.2% CAGR
Longevity Therapeutics Market
$872.0 Mn in 2025 · 22.1% CAGR